glp 1 agonist vision loss Doctors are tracking rare reports of alongside accelerated facial aging caused by rapid weight loss from GLP-1 medications. MORE BELOW ⬇️ A potentially blinding condition is

This transport step is the rate-limiting bottleneck in fat oxidation: without adequate carnitine availability, fatty acids cannot efficiently enter the mitochondria for energy production regardless of how much stored fat is available

GLP-1 receptor agonists may be appropriate for individuals who: Have a body mass index (BMI) of 35 kg/m or higher (or lower thresholds32.5 kg/m or abovefor people from Black, Asian, and other minority ethnic groups) and would benefit from weight loss Have established cardiovascular disease or are at high cardiovascular risk (certain GLP-1 receptor agonists have demonstrated cardiovascular benefits in clinical trials) Have chronic kidney disease (CKD) or heart failure, where specific agents may offer additional protection Require additional glucose-lowering therapy but wish to avoid weight gain associated with some other diabetes medicines Cannot tolerate or have contraindications to other glucose-lowering therapies NICE NG28 continuation criteria : GLP-1 receptor agonist therapy should be continued beyond 6 months only if the person has had a beneficial metabolic response , defined as a reduction of at least 11 mmol/mol (1.0%) in HbA1c and a weight loss of at least 3% of initial body weight

Bull Natl Res Cent 48 , 100 (2024)

Shishehbor, M